Hepatitis C Virus. Current and Evolving Treatments for Genotype 4

Gastroenterology Clinics of North America

Volumn 44, Issue 4, 2015, Pages 859-870

  Asselah, Tarik ^a   Bourlière, Marc ^b  

^a INSERM   (France)

^b HÔPITAL SAINT JOSEPH   (France)

Author keywords

Access to treatment; Direct acting antivirals; Egypt; Ledipasvir; Ombitasvir; Paritaprevir; Screening; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; BECLABUVIR; DACLATASVIR; ELBASVIR; GRAZOPREVIR; INTERLEUKIN 28B; LEDIPASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

AFRICA SOUTH OF THE SAHARA; AFRICAN; ASTHENIA; CAUCASIAN; CHRONIC LIVER DISEASE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EGYPTIAN; EUROPE; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INSOMNIA; MIDDLE EAST; MULTICENTER STUDY (TOPIC); NAUSEA; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PREVALENCE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; TREATMENT OUTCOME;

EID: 84947584604     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2015.07.013     Document Type: Review

References (28)

1. Abdel-Razek W., Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured?. Liver Int 2015, 35(Suppl 1):27-34.
2. Messina J.P., Humphreys I., Flaxman A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015, 61(1):77-87.
3. Gower E., Estes C., Blach S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014, 61(Suppl 1):S45-S57.
4. Frank C., Mohamed M.K., Strickland G.T., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355(9207):887-891.
5. Smith D.B., Bukh J., Kuiken C., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014, 59:318-327.
6. Marcellin P., Cheinquer H., Curescu M., et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012, 56(6):2039-2050.
7. Mauss S., Berger F., Vogel M., et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012, 50(5):441-444.
8. Asselah T., De Muynck S., Broët P., et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012, 56(3):527-532.
9. Estrabaud E., Vidaud M., Marcellin P., et al. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012, 57:1110-1125.
10. Schinazi R., Halfon P., Marcellin P., et al. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014, 34(Suppl 1):69-78.
11. Wendt A., Adhoute X., Castellani P., et al. Chronic hepatitis C: future treatment. Clin Pharmacol 2014, 6:1-17.
12. Asselah T. Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available. J Hepatol 2015, 62(5):996-999.
13. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
14. Moreno C., Hezode C., Marcellin P., et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015, 62(5):1047-1055.
15. Hézode C., Hirschfield G.M., Ghesquiere W., et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2015, 64(6):948-956.
16. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2014, 15:121-130.
17. Gao M., Nettles R.E., Belema M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465:96-100.
18. Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol 2011, 54:1069-1072.
19. Ruane P.J., Ain D., Stryker R., et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015, 62(5):1040-1046.
20. Doss W., Shiha G., Hassany M., et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015, 63(3):581-585.
21. Kapoor R., Kohli A., Sidharthan S., et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID Synergy Trial. Hepatology 2014, 60:321A. [abstract].
22. Abergel A., Loustaud-Ratti V., Metivier S., et al. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. J Hepatol 2015, 62(Suppl 2):S219.
23. Fontaine H., Hézode C., Zoulim F., et al. Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the French observational cohort ANRS CO22 HEPATHER. J Hepatol 2015, 62(Suppl 2):S278.
24. Hézode C., Asselah T., Reddy K.R., et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomized, open-label trial. Lancet 2015, 385(9986):2502-2509.
25. Hassanein T., Sims K.D., Bennett M., et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol 2015, 62(5):1204-1206.
26. Asselah T., Hassanein T., Qaqish R.B., et al. A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis. J Hepatol 2015, 62(Suppl 2):S1345.
27. Asselah T., Charlton M., Feld J., et al. The ASTRAL studies: evaluation of SOF/GS-5816 single tablet regimen for the treatment of genotype 1-6 HCV infection. J Hepatol 2015, 62(Suppl 2):S1332.
28. Asselah T., Perumalswami P.V., Dieterich D. Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity. Liver Int 2014, 34(10):1447-1451.